Science Corp. Receives EU Approval to Sell PRIMA Retinal Implant, First U.S. BCI Device in Patient Market

According to Science Corp., the company received approval to sell its PRIMA retinal implant system in the European Union, marking the first large-scale market launch of a brain-computer interface device by a U.S. BCI company. The photovoltaic retinal implant is designed to help patients with geographic atrophy (GA) restore partial vision. The system works with specialized glasses that project near-infrared light onto the implant, converting it into electrical stimulation signals. The technology includes a magnification function allowing patients to enlarge text. The implant is ultrathin and features wireless integration.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments